Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

被引：3
|
作者：
Lust, John A.
Barranco, Charles
Usmani, Saad Z.
van Rhee, Frits
Hamadani, Mehdi
Thompson, John
Taylor, Catherine A.
Dondero, Richard
Browne, Leslie J.
Siegel, David
Bensinger, William I.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1950.1950
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1950
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
    Lust, John A.
    Usmani, Saad Z.
    Hamadani, Mehdi
    Barranco, Charles
    Lacy, Martha Q.
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen
    Buadi, Francis K.
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    BLOOD, 2012, 120 (21)
  • [2] Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
    Lust, John Anthony
    Barranco, Charles
    Lacy, Martha
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen J.
    Buadi, Francis
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Usmani, Saad Zafar
    Thompson, John
    Taylor, Catherine
    Dondero, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies
    Siegel, David S.
    McDonald, Andrew
    Novitzky, Nicolas
    Bensinger, William
    Craig, Michael
    van Rhee, Frits
    Gutierrez, Martin
    Libby, Edward N.
    Thompson, John
    Bexon, Alice S.
    Barranco, Charles
    Taylor, Catherine A.
    Dondero, Richard
    Browne, Leslie J.
    Kurman, Michael R.
    Lust, John A.
    BLOOD, 2014, 124 (21)
  • [4] Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies
    Craig, Michael
    Bensinger, William
    Siegel, David Samuel DiCapua
    Van Rhee, Frits
    Novitzky, Nicolas
    Mcdonald, Andrew
    Gutierrez, Martin
    Libby, Edward N.
    Thompson, John
    Belton, Alice Susannah
    Barranco, Charles
    Taylor, Catherine
    Dondero, Richard
    Browne, Leslie J.
    Kurman, Michael R.
    Lust, John Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
    Dholaria, Bhagirathbhai
    Mamuye, Admasu
    Yurewicz, Diana
    Dabovic, Kristina
    Yuet, Amy
    Abonour, Rafat
    Kelly, Kevin R.
    Voorhees, Timothy J.
    Kazandjian, Dickran
    BLOOD, 2022, 140 : 12621 - 12622
  • [6] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [7] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
    Kumar, Shaji
    Mamuye, Admasu
    Dabovic, Kristina
    Wang, Jingyuan
    Roy, Vivek
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S11
  • [8] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
    Luscan, Gerald
    Paccagnella, Luisa
    Patel, Krish
    BLOOD, 2023, 142
  • [9] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    HAEMATOLOGICA, 2018, 103 : 32 - 33
  • [10] A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
    Walling, Jackie M.
    Matusow, Bernice
    Nichols, Christine
    Singh, Parmveer
    Inokuchi, Kerry
    Bollag, Gideon
    BLOOD, 2024, 144 : 7022 - 7023
12345